Under-the-skin Injection of Tysabri Approved in Europe

Under-the-skin Injection of Tysabri Approved in Europe

291410

Under-the-skin Injection of Tysabri Approved in Europe

The European Commission (EC) has approved a new method to administer Tysabri (natalizumab) as a treatment for people with relapsing-remitting multiple sclerosis (RRMS). This new delivery route involves a subcutaneous injection in which Tysabri is injected under the skin. Compared with the previously approved intravenous (into the bloodstream) formulation, this one can be given in less time, in settings beyond infusion centers, and requires no or shorter post-observation periods after the first six doses. It also…

You must be logged in to read/download the full post.